University of Miami Health System Desai Sethi Urology Institute

The Desai Sethi Urology Institute (DSUI) has released its 2025 Annual Report.

The conversation tackles testosterone therapy in men with prostate cancer, a complex and sometimes controversial issue.

Award-winning COO of UHealth, renowned surgeon scientist, and director of the Desai Sethi Urology Institute elevated to lead patient-focused care, biomedical research, and medical education

"I would say, talk to each other. Talk to other men about it. You are not the only one leaking," says Vanita Gaglani, RPT.

“We hypothesized based on prior work that specifically men with low-volume disease, if they inherit this hyperactive form of HSD3B1, they'll have shorter overall survival. It turns out that that's true,” says Nima Sharifi, MD.

“Of the 3 adrenal androgens, it's DHEA that seems to be most indicative of overall survival,” says Nima Sharifi, MD.

Smerina and Pearlman discuss recent research collaborations in the field of sexual medicine.

"A lot of shared decision-making has to do with, what is important to the individual man?" says Dean S. Elterman, MD, MSc, FRCSC.

"My second book is on pelvic pain or prostatitis. It is focused on a holistic approach and stretches and mindfulness exercises," says Vanita Gaglani, RPT.

"Most of these comorbidities, while they do affect the bladder, don't seem to affect the surgeries for stress urinary incontinence," says Jaspreet S. Sandhu, MD.

"There are actually no data to support that 1 neuromodulation is better than another based on disease severity, and this is based on the systematic review done for the OAB guideline," says Anne Pelletier Cameron, MD, FRCSC, FPMRS.

"It really remains to be seen whether we can expand this to care for other types of urological inpatients," says Timothy D. Lyon, MD.

"There are some very strict IC diets that have been published, and I've had a handful of patients who have really found them helpful," says J. Quentin Clemens, MD, MSCI.

"I use a multi-pronged approach. I focus on behavior modification, nutrition, hydration, and exercise," says Vanita Gaglani, RPT.

The report, titled "TRANSFORMATION: From an academic department to a leading Institute," highlights DSUI's transformation from a department into a multidisciplinary institute.

"I know this year we're going to see even more companies producing more products, more results, and hopefully really help change and improve patient outcomes, especially when it comes to overactive bladder," says Raveen Syan, MD, FPMRS.

"If you can do this surgery well, patients actually go back to living a normal life, and they're immensely, immensely happy," says Jaspreet S. Sandhu, MD.

"The approach is often to identify what treatments the patients have tried already, so we don't try those again, and then have a discussion about the pros and cons," says J. Quentin Clemens, MD, MSCI.

"At Mayo Clinic, we think that delivering intravesical therapy for non-muscle invasive bladder cancer in patients' homes has the potential to reduce treatment burden, improve the patient experience, as well as increase access to care," says Timothy D. Lyon, MD.

"There is new technology emerging for skin stimulation of the perineum that is just recently evolving to help control OAB symptoms," says Anne Pelletier Cameron, MD, FRCSC, FPMRS.

"What's unique about our conference is the focus is not on just showcasing what our institute has to offer; the real focus is on networking and collaborating with the top institutes in the nation," says Raveen Syan, MD, FPMRS.

"While our results may imply that a strict all-business professionalism is superior, I think it's important to acknowledge that humor is really subjective," says Max D. Sandler.

here was a higher concordance of somatic alterations between tissue and ctDNA testing in patients with metastases vs those without.

“Across the whole survey, an average of 66% preferred the professional card. The highest rate of selection of the humorous card in a single question was only 38.4%,” says Max D. Sandler.

“We are trying to evaluate the ctDNA role in prognostication as well,” says Chinmay Jani, MD.

"There is a hypothesis that nectin-4 as a potential target for antibody drug conjugates, such as EV, potentially should work," says Marijo Bilusic, MD, PhD.

Raveen Syan, MD, highlights 2 sessions that she took part in during the 2024 AUA Annual Meeting in San Antonio, Texas on urodynamics in the context of the VALUE trial and the new wave of percutaneous tibial nerve stimulation devices.

"Every time I leave the meeting, I just feel reinvigorated, refreshed, and excited about this field that we're a part of," says Raveen Syan, MD, FPMRS.

The investigators at DSUI developed 4 recommended actions for urologists based on the findings from the survey: drive multidisciplinary collaboration, leverage technology excellence, bridge patient-urologist perspectives, and foster collaboration with general practitioners.